TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20405011
Drug: Self-administered HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered HAART
Study: 18676757
Drug: ALVAC-CEA/B7.1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-CEA/B7.1 vaccine followed by chemotherapy (group 1)
Study: 18676757
Drug: ALVAC-CEA/B7.1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-CEA/B7.1 vaccine with tetanus toxoid adjuvant followed by chemotherapy (group 2)
Study: 18676757
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by ALVAC-CEA/B7.1 vaccine (group 3)
Study: 8553592
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (all groups)
Study: 18676757
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (group 3)
Study: 15009104
Drug: Calcipotriol monotherapy
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol monotherapy
Study: 15463842
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice daily with routine treatment for four months
Study: 10816408
Drug: Buscopan (hyoscine-N-butylbromide)
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan (hyoscine-N-butylbromide) 20 mg administered before barium infusion (Group A)
Study: 10816408
Drug: Buscopan (hyoscine-N-butylbromide)
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan (hyoscine-N-butylbromide) 20 mg administered after barium infusion and gas insufflation (Group B)
Study: 8666605
Drug: Preoperative irradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative irradiation (800 centigray dose)
Study: 8666605
Drug: Postoperative irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative irradiation (800 centigray dose)
Study: 1876282
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acid infusion (90 min)
Study: 1876282
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acid infusion (30 min)
Study: 1876282
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acid infusion (both protocols)
Study: 6871775
Drug: Succinylcholine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 2% solution
Study: 6871775
Drug: Succinylcholine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 5% solution
Study: 27795368
Drug: MEDI4893 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4893 at 225 mg
Study: 27795368
Drug: MEDI4893 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4893 at 750 mg
Study: 27795368
Drug: MEDI4893 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4893 at 2,250 mg
Study: 27795368
Drug: MEDI4893 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4893 at 5,000 mg
Study: 25170833
Drug: GH(67) (67
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH(67) (67 µg/kg/day)
Study: 25170833
Drug: GH(33×1) (33
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH(33×1) (33 µg/kg/day)
Study: 25170833
Drug: GH(67×1) (67
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH(67×1) (67 µg/kg/day)
Study: 25170833
Drug: GH(33×2) (67
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH(33×2) (67 µg/kg/day)
Study: 24659740
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) treatment
Study: 17683094
Drug: Family-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based therapy
Study: 3318444
Drug: Indomethacin 150
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 150 mg
Study: 7617236
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.1 mg x kg‐1 + oral clonidine 5 micrograms x kg‐1 (Group B)
Study: 7617236
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.1 mg x kg‐1 + i.m. clonidine 4 micrograms x kg‐1 (Group C)
Study: 7617236
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.1 mg x kg‐1 (Group A)
Study: 2611446
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of salmon calcitonin nasal spray (sCT‐NS)
Study: 2611446
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of salmon calcitonin nasal spray (sCT‐NS)
Study: 330322
Drug: Hydrochlorothiazide +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide + triamterene treatment with or without methyldopa
Study: 330322
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of hypotensive therapy
Study: 330322
Drug: Hypotensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive therapy
Study: 31123057
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) therapy at flows of 8-2 L/min
Study: 31343947
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acid supplementation (EAAs) - 20 g, twice daily for 7 days before TKA and for 6 weeks after surgery
Study: 26950740
Drug: Subcutaneous talc
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous talc
Study: 23258530
Drug: Low-dose pegylated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pegylated interferon (IFN)
Study: 16703971
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of hypertonic dextrose (50% dextrose and 0.25% Bupivacaine)
Study: 15155329
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg succinylcholine
Study: 14576536
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg succinylcholine
Study: 14576536
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg succinylcholine
Study: 15155329
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg succinylcholine
Study: 9701409
Drug: Theophylline (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (median dose 250 mg twice daily; range 250-375 mg twice daily)
Study: 2811065
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg (F)
Study: 2811065
Drug: Chlorothiazide 500
Normalized name: chlorothiazide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide 500 mg (C)
Study: 2811065
Drug: Furosemide with
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide with spironolactone (100 mg b.i.d.) (F + S)
Study: 2811065
Drug: Chlorothiazide during
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorothiazide during furosemide infusion
Study: 29166987
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release (MFR) treatment, four 20-minute sessions at weekly intervals.
Study: 23274511
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg recombinant hCG
Study: 23274511
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg recombinant hCG
Study: 16498861
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg for 14 days
Study: 10499754
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg (1 mL) clonidine
Study: 10499754
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL preservative‐free normal saline mixed with local anesthetic (7 mL 1% preservative‐free lidocaine)
Study: 8815563
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (oral coumadin or standard intravenous heparin)
Study: 7226713
Drug: Nitrofurantoin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (50 mg) administered via intravenous infusion
Study: 7226713
Drug: Nitrofurantoin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (50 mg) oral tablet
Study: 7226713
Drug: Nitrofurantoin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (50 mg)
Study: 26299540
Drug: Fixed, low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed, low radiant exposure diode laser treatments
Study: 26299540
Drug: Incremental radiant
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental radiant exposure diode laser treatments
Study: 25336915
Drug: Evogliptin 20
Normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin 20 mg
Study: 8481018
Drug: Acyclovir suppressive
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir suppressive therapy (400 mg twice daily)
Study: 30890624
Drug: Adapalene Gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene Gel 0.1%
Study: 21505722
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5,000 IU t.i.d.
Study: 21746765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aliskiren and losartan
Study: 16145378
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of intravesical BCG (81 mg)
Study: 16145378
Drug: Decreased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased dose of intravesical BCG (27 mg)
Study: 11793426
Drug: Tolcapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (200 mg) with levodopa/carbidopa (100/125 mg)
Study: 11793426
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with levodopa/carbidopa (100/125 mg)
Study: 7977607
Drug: 100,000-IU dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000-IU dose of vitamin A
Study: 7977607
Drug: 200,000-IU dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000-IU dose of vitamin A
Study: 17885543
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard vs ACE inhibitors
Study: 15166882
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine (100 mCi iodine-131)
Study: 12237621
Drug: Levormeloxifene 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene 0.5 mg daily
Study: 12237621
Drug: Levormeloxifene 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene 1.25 mg daily
Study: 7865643
Drug: Bran supplementation
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran supplementation (12 g/day)
Study: 2717904
Drug: 0.01% (w/v)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% (w/v) PGE1 solution in saline injected under the mucoperiosteum palatal to the test tooth
Study: 24660584
Drug: Modified Sishen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Sishen Wan (treatment group A)
Study: 12648685
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day
Study: 2068563
Drug: Defibrotide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 400 mg three times daily
Study: 6185109
Drug: Short‐course, high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short‐course, high fractional dose radiation therapy (6,000 to 7,000 rad in six to seven weeks)
Study: 30570087
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture at energy balance points and points indicated for pain treatment.
Study: 24642984
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (200 µg)
Study: 24642984
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol (50 µg for 7 days)
Study: 19171852
Drug: Bivalirudin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin with or without IIb/IIIa inhibitors
Study: 16342093
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice weekly subcutaneously
Study: 10598302
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with milnacipran
Study: 7721386
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 to 8 mg/d)
Study: 7721386
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg/d)
Study: 1974271
Drug: Controlled Release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled Release (CR) 200 mg, administered b.i.d.
Study: 1974271
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) 200 mg, administered b.i.d.
Study: 4018423
Drug: Unchanged conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged conventional treatment (UCT)
Study: 24290406
Drug: Ondansetron pretreatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron pretreatment (4 mg)
Study: 20541000
Drug: Cutanova Nanorepair
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cutanova Nanorepair Q10 cream
Study: 20541000
Drug: NLC negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLC negative control cream
Study: 18085432
Drug: Self‐administered therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered therapy (SAT)
Study: 1408571
Drug: Oral antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antimicrobial agents
Study: 6275778
Drug: Parenteral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotics
Study: 1408571
Drug: Change from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change from parenteral to oral antibiotics
Study: 3048053
Drug: Clonidine (75-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (75-300 micrograms daily)
Study: 29392280
Drug: TTFields therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFields therapy
Study: 23422605
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg)
Study: 23422605
Drug: Acetaminophen (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (325 mg)
Study: 23422605
Drug: Calcium vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium vs Acetaminophen
Study: 20389249
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (2.4 g)
Study: 16179955
Drug: Meptin DPI
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptin DPI (20 mcg)
Study: 16179955
Drug: Meptin MDI
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptin MDI (20 mcg)
Study: 12543895
Drug: Radiocephalic AVF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiocephalic AVF creation with surgical and interventional treatment
Study: 10869893
Drug: 10% Lipofundin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Lipofundin MCT/LCT (1.5 g. kg. d)
Study: 10869893
Drug: 10% LCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% LCT (1.5 g. kg. d)
Study: 25040325
Drug: Twice-daily application
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily application of a commercially available, standardised pH neutral, perfume-free moisturiser on extremities.
Study: 25040325
Drug: Twice-daily application
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily application of moisturiser.
Study: 12360554
Drug: Olanzapine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5-10 mg/day to effect)
Study: 1575056
Drug: nHuIFN-alpha and
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nHuIFN-alpha and nHuTNF-alpha combination (10 micrograms of nHuIFN-alpha and 3 micrograms of nHuTNF-alpha) injected intravenously at a maintenance dose of more than 2 x 10(6)U/day for over 8 weeks
Study: 1575056
Drug: nHuIFN-alpha and
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nHuIFN-alpha and nHuTNF-alpha combination at a maintenance dose of 1 x 10(6)U/day
Study: 3906426
Drug: Tiapride (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (600 mg/day)
Study: 31228455
Drug: Curcumin (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (480 mg nanomicelle curcumin orally)
Study: 29354951
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Chinese medicine of artificial cycle therapy
Study: 29354951
Drug: Letrozole and
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole and metformin (control group)
Study: 21515027
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy (VRE)
Study: 16432600
Drug: 2% tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% tea lotion applied twice daily for 2 months
Study: 12891305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving lipid lowering drugs)
Study: 8302982
Drug: Nicotine fading
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine fading and concurrent smokeholding
Study: 8302982
Drug: Intensive smokeholding
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive smokeholding programme (daily sessions)
Study: 3574823
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg medroxyprogesterone acetate for days 1-28
Study: 3574823
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg medroxyprogesterone acetate for days 1-28
Study: 3574823
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg medroxyprogesterone acetate for days 17-28
Study: 21126856
Drug: Inotropic contractile
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotropic contractile reserve (ICR) assessed by low-dose dobutamine stress echocardiography
Study: 10890580
Drug: Macorel tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macorel tablets (test preparation)
Study: 10890580
Drug: Adalat tablets
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adalat tablets (reference preparation)
Study: 31064021
Drug: Medial pivot
Normalized name: Picot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial pivot (MP) implant
Study: 31389278
Drug: Daily rhythm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhythm of distal skin temperature (DST)
Study: 25078334
Drug: Brodalumab (antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab (antibody to interleukin-17 receptor A)
Study: 9508522
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of erythromycin during fasting state
Study: 9508522
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of erythromycin plus 300 ml of fresh milk (postprandial state)
Study: 9508522
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml of fresh milk and normal saline as placebo (postprandial state)
Study: 7395780
Drug: Intravenous supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous supplements of essential or essential and nonessential amino acids for 2 months
Study: 31774510
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) + Radial Extracorporeal Shock Wave Therapy (rESWT)
Study: 24000594
Drug: Polysaccharide 23-valent
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide 23-valent pneumococcus vaccine (Pneumo 23, Sanofi Pasteur, France)
Study: 19232899
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily for 1 to 8 weeks
Study: 16433794
Drug: Aspirin challenge
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin challenge test in family 1
Study: 16433794
Drug: Aspirin challenge
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin challenge test in family 2
Study: 12605339
Drug: Computer-assisted navigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted navigation system (CAS) for acetabular implant positioning
Study: 1831908
Drug: RU 41
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 41 656 (10 mg)